<div id="readability-page-1"><p>Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report)'s share price dropped 4.2% on Tuesday . The stock traded as low as $24.60 and last traded at $25.05. Approximately 101,949 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 576,602 shares. The stock had previously closed at $26.14.</p><div><p><span></span><span>Get <strong>Kodiak Sciences</strong> alerts:</span></p></div><h2>Wall Street Analyst Weigh In</h2><p>A number of research firms have issued reports on KOD. HC Wainwright boosted their price objective on shares of Kodiak Sciences from $24.00 to $26.00 and gave the company a &#34;buy&#34; rating in a report on Monday, November 17th. Weiss Ratings  reissued a &#34;sell (e+)&#34; rating on shares of Kodiak Sciences in a research report on Wednesday, October 8th. Barclays upgraded Kodiak Sciences from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating and raised their price objective for the stock from $7.00 to $17.00 in a research note on Thursday, September 25th. Jefferies Financial Group began coverage on Kodiak Sciences in a research report on Monday, September 22nd. They set a &#34;buy&#34; rating and a $15.00 target price for the company. Finally, Chardan Capital  restated a &#34;neutral&#34; rating and issued a $14.00 price target on shares of Kodiak Sciences in a research report on Monday, November 17th. Four equities research analysts have rated the stock with a Buy rating, two have issued  a Hold rating and one  has assigned  a Sell rating to the company. According to MarketBeat.com, Kodiak Sciences  has an average rating of &#34;Hold&#34; and a consensus price target of $22.67.</p><p><b>Check Out Our Latest Stock Report on KOD</b></p><h2>Kodiak Sciences Stock Performance</h2><p>The company has a market cap of $1.35 billion, a price-to-earnings ratio of -6.15 and a beta of 2.68. The business has a fifty day moving average price of $18.49 and a 200 day moving average price of $11.08. </p><p>Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its earnings results on Thursday, November 13th. The company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.09).  As a group, equities analysts anticipate that  Kodiak Sciences Inc. will post -3.45 EPS for the current year. </p><h2>Hedge Funds Weigh In On Kodiak Sciences</h2><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. US Bancorp DE raised its holdings in  Kodiak Sciences by 131.7% in the 1st quarter. US Bancorp DE now owns 9,282 shares of the company's stock valued at $26,000 after buying an additional 5,276 shares during the last quarter.  Headlands Technologies LLC raised its stake in shares of  Kodiak Sciences by 256.4% during the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock valued at $30,000 after acquiring an additional 5,815 shares during the last quarter.  Walleye Capital LLC acquired a new position in shares of  Kodiak Sciences during the first quarter worth $49,000.  Vanguard Personalized Indexing Management LLC grew its stake in shares of  Kodiak Sciences by 21.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company's stock worth $56,000 after purchasing an additional 2,691 shares during the last quarter.  Finally, Russell Investments Group Ltd. grew its stake in shares of  Kodiak Sciences by 729.9% in the first quarter. Russell Investments Group Ltd. now owns 21,039 shares of the company's stock worth $59,000 after purchasing an additional 18,504 shares during the last quarter. Institutional investors own  89.06% of the company's stock. </p><h2>About Kodiak Sciences</h2> (Get Free Report)<p>Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Kodiak Sciences</li><li>Investing in the High PE Growth Stocks </li><li>Carvana Soars Over 10,000% From Lows—Now It’s in the S&amp;P 500</li><li>How to Plot Fibonacci Price Inflection Levels </li><li>UiPath Surges on Earnings: Should Investors Chase the Momentum?</li><li>How to Capture the Benefits of Dividend Increases</li><li>Pure Storage's 27% Fall: Real Opportunity or Deserved Correction?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Kodiak Sciences Right Now?</h2><p>Before you consider Kodiak Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.</p><p>While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Kodiak Sciences (NASDAQ:KOD) stock dropped 4.2% to $25.05, with trading volume down 82% from average. Analysts have mixed ratings, with a consensus price target of $22.67. The company reported a quarterly EPS of ($1.16), missing estimates. Institutional investors hold 89.06% of shares. Kodiak Sciences focuses on retinal disease therapeutics, with its lead product in Phase IIb/III trials.</p>

Kodiak Sciences (NASDAQ:KOD) Stock Price Down 4.2% - Here's Why